Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer
The combination of sintilimab with nab-paclitaxel + S-1 for neoadjuvant treatment of LAGC improved efficacy in patients without increasing adverse drug reactions and perioperative adverse events, suggesting that this treatment regimen is safe and feasible.
Authors
- Rongjie Huang
- Weiming Zeng (ORCID: https://orcid.org/0000-0002-9035-8078)
- Yue Cai (ORCID: https://orcid.org/0000-0001-6803-2680)
- Meng Lian (ORCID: https://orcid.org/0000-0003-2509-4958)
- Chen-Bin Lv
- Mingqiao Lian
- Yongbin Zhang (ORCID: https://orcid.org/0000-0003-4198-5793)
- Wei Lian (ORCID: https://orcid.org/0000-0002-8023-5138)
- Qianhui Xu (ORCID: https://orcid.org/0000-0003-3394-1491)
- Yuqin Sun (ORCID: https://orcid.org/0009-0008-4067-732X)
- Li‐Sheng Cai (ORCID: https://orcid.org/0000-0002-9762-878X)
- Qiu‐Xian Chen
Institutions
- Nanjing Tech University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Surgery
- Published
- 2025-05-29
- DOI
- https://doi.org/10.4240/wjgs.v17.i6.106361
- Citations
- 3
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.56